|
Re: Just back from IR,...
|
2
|
Resverlogix Corp.
|
Oct 29, 2019 10:05AM
|
|
Re: Just back from IR,...
|
7
|
Resverlogix Corp.
|
Oct 28, 2019 08:51PM
|
|
Re: Zenith MD&A and Financials are up
|
7
|
Zenith Epigenetics
|
Oct 28, 2019 03:36PM
|
|
Bioasis Announces Bridge Financing
|
2
|
BIOASIS TECHNOLOGIES INC
|
Oct 28, 2019 01:52PM
|
|
Re: Just back from IR,...
|
4
|
Resverlogix Corp.
|
Oct 27, 2019 06:39PM
|
|
Re: Just back from IR,...
|
2
|
Resverlogix Corp.
|
Oct 27, 2019 03:03PM
|
|
Re: Just back from IR,...
|
7
|
Resverlogix Corp.
|
Oct 26, 2019 09:11AM
|
|
Re: Just back from IR,...
|
7
|
Resverlogix Corp.
|
Oct 25, 2019 11:03PM
|
|
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2019
|
1
|
BIOASIS TECHNOLOGIES INC
|
Oct 25, 2019 10:39PM
|
|
Re: Few Nuggets in the MD&A
|
2
|
BIOASIS TECHNOLOGIES INC
|
Oct 25, 2019 10:23PM
|
|
Re: Just back from IR,...
|
1
|
Resverlogix Corp.
|
Oct 25, 2019 08:34PM
|
|
Re: 8 Minutes at AHA
|
5
|
Resverlogix Corp.
|
Oct 25, 2019 05:00PM
|
|
Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
|
5
|
Zenith Epigenetics
|
Oct 25, 2019 09:59AM
|
|
ZEN-3694 the first pan-BET inhibitor in Phase 3?
|
5
|
Zenith Epigenetics
|
Oct 25, 2019 09:48AM
|
|
New Zenith immuno-oncology trial with Keytruda
|
4
|
Zenith Epigenetics
|
Oct 25, 2019 09:29AM
|
|
Re: Q4 2019 Events
|
4
|
Resverlogix Corp.
|
Oct 25, 2019 08:16AM
|
|
Re: BIO Investor Forum, Oct 22-23
|
6
|
Zenith Epigenetics
|
Oct 24, 2019 11:40PM
|
|
Re: 8 Minutes at AHA
|
4
|
Resverlogix Corp.
|
Oct 24, 2019 09:54PM
|
|
Re: 8 Minutes at AHA
|
4
|
Resverlogix Corp.
|
Oct 24, 2019 08:33PM
|
|
8 Minutes at AHA
|
10
|
Resverlogix Corp.
|
Oct 24, 2019 06:57PM
|
